此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

裸盖菇素治疗慢性腰痛 (POP)

2026年11月3日 更新者:Joshua Woolley, MD, PhD

一项双盲、随机试验,检验裸盖菇素治疗慢性腰痛患者的初步疗效

This study evaluates whether psilocybin therapy helps patients cope with chronic low back pain more effectively. Patients may be recruited at Stanford and University of California San Francisco (UCSF), study procedures will occur at UCSF. Each participant will receive a dose of psilocybin with possibly one or more other drugs. Participants will undergo two preparation sessions, a dosing session, three integration sessions to discuss their psilocybin experience, and several follow up sessions.

研究概览

详细说明

Chronic pain is associated with higher levels of pain-related distress, depression, emotional dysfunction, helplessness, hopelessness, and suicidality. Psilocybin is a psychoactive drug that may be well-suited to easing the psychological and emotional symptoms of distress associated with chronic pain. Previous studies testing psilocybin therapy have shown improvements on multiple behavioral and psychiatric outcomes, but it is unknown whether psilocybin therapy similarly enables patients to cope with chronic pain more effectively. The investigators will determine whether psilocybin therapy improves patients' ability to cope with chronic low back pain. If psilocybin therapy is an effective treatment in this population, its use could be incorporated into interventions for chronic low back pain and other psychological conditions.

研究类型

介入性

注册 (实际的)

40

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • San Francisco、California、美国、94107
        • University of California San Francisco

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

25年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 25 to 70 years old
  • Comfortable speaking and writing in English
  • Diagnosed with chronic low back pain
  • Able to attend all in-person visits at UCSF as well as virtual visits
  • Has tried at least two previous medications/ procedures and physical therapy trials for low back pain

Exclusion Criteria:

  • Chronic low back pain that is attributed to malignancy, subacute or acute fracture or infection
  • Low back pain with radiation below the knee
  • Low back pain with neurologic signs present
  • Regular use of medications that may have problematic interactions with psilocybin, including but not limited to dopamine agonists, MAO inhibitors, antipsychotics, and stimulants
  • A health condition that makes study unsafe or unfeasible, determined by study physicians

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Psilocybin in combination with Zolpidem and Modafinil

Single dose of Psilocybin (1mg-30mg) in combination with zolpidem and modafinil

1-30 mg (oral administration), Modafinil (oral administration), and Zolpidem (oral administration)

其他名称:
  • 4-磷酰氧基-N,N-二甲基色胺
实验性的:Psilocybin in combination with Zolpidem

Single dose of Psilocybin (1mg-30mg) in combination with zolpidem

1-30 mg (oral administration), Zolpidem (oral administration), and placebo (oral administration)

其他名称:
  • 4-磷酰氧基-N,N-二甲基色胺
实验性的:Psilocybin in combination with Modafinil

Single dose of Psilocybin (1mg-30mg) in combination with modafinil

1-30 mg (oral administration), Modafinil (oral administration), and placebo (oral administration)

其他名称:
  • 4-磷酰氧基-N,N-二甲基色胺
实验性的:Psilocybin in combination with Placebo

Single dose of Psilocybin (1mg-30mg) in combination with placebo

1-30 mg (oral administration), and placebo (oral administration)

其他名称:
  • 4-磷酰氧基-N,N-二甲基色胺

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in pain interference
大体时间:Baseline, 1-month after psilocybin session

The Brief Pain Inventory-Interference subscale (BPI) will be used to assess how pain interferes with a variety of daily activities (e.g., walking, lifting, mood, sleep, relationships). Seven items are rated on a scale from 0 (does not interfere) to 10 (completely interferes) for a total possible score ranging from 0 to 70. Higher scores represent greater interference from pain.

Baseline, 1-month after psilocybin session

次要结果测量

结果测量
措施说明
大体时间
Change in pain interference
大体时间:Baseline, 1-week, and 3-months

The Brief Pain Inventory-Interference subscale (BPI) will be used to assess how pain interferes with a variety of daily activities (e.g., walking, lifting, mood, sleep, relationships). Seven items are rated on a scale from 0 (does not interfere) to 10 (completely interferes) for a total possible score ranging from 0 to 70. Higher scores represent greater interference from pain.

Baseline, 1-week, and 3-months
Change in average pain intensity
大体时间:Baseline, 1-week, 1-month, and 3-months after psilocybin session

The Brief Pain Inventory with the Michigan Body Map will be used to assess pain location and worst, least, average, and present pain on a numerical rating scale from 0 (no pain) to 10 (pain as bad as you can imagine) over the past 24 hours, where higher scores represent greater pain intensity.

Baseline, 1-week, 1-month, and 3-months after psilocybin session
Change in clinical depressive symptom severity
大体时间:Baseline, 1-week, 1-month, and 3-months after psilocybin session

The 17-item clinician administered Hamilton Rating Scale for Depression will be used to assess changes in the severity of depressive symptoms. Each item is scored by a clinician on a 3- or 5-point scale from 0 (Not present) to 4 (severe) and summed for a total score between 0 and 52. A higher total score represents greater depressive symptom severity.

Baseline, 1-week, 1-month, and 3-months after psilocybin session
Change in depressive symptom severity
大体时间:Baseline, pre-dosing session, 5-days, 11-days, and 77-days after psilocybin session

The 7-item PROMIS-Depression self-report scale will be used as an additional indicator for changes in depression symptom severity. Items are endorsed on a 5-point scale ranging from 1 (Never) to 5 (Always). A higher total score represents greater depressive symptom severity.

Baseline, pre-dosing session, 5-days, 11-days, and 77-days after psilocybin session

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Joshua Woolley、University of California, San Francisco

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年12月1日

初级完成 (实际的)

2026年8月7日

研究完成 (实际的)

2026年8月7日

研究注册日期

首次提交

2022年4月22日

首先提交符合 QC 标准的

2022年4月22日

首次发布 (实际的)

2022年4月28日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅